Alternatives to clopidogrel for acute coronary syndromes:Prasugrel or ticagrelor?  

作　　者：Giuseppe Biondi-Zoccai Marzia Lotrionte Fiorenzo Gaita 

机构地区：[1]Division of Cardiology,University of Turin,San Giovanni Battista "Molinette" Hospital [2]Unit for Heart Failure and Cardiac Rehabilitation,Catholic University

出　　处：《World Journal of Cardiology》2010年第6期131-134,共4页世界心脏病学杂志（英文版）（电子版）

摘　　要：Clopidogrel is a mainstay in the treatment of patients with acute coronary syndromes or those receiving endovascular prostheses.However,its efficacy has been challenged in the recent past by studies suggesting variable individual responsiveness and by new,more potent competitors,such as prasugrel and ticagrelor. But what is the actual body of evidence in support of clopidogrel?Is there any dark side of the moon?What is the role of prasugrel,which has already been approved in Europe and in the United States?And what will be the future role of ticagrelor,when approved for routine clinical practice?We hereby concisely summarize the scope of this clinical choice,providing arguments in favor and against each of the three antiplatelet agents:clopidogrel,prasugrel,and ticagrelor.Clopidogrel is a mainstay in the treatment of patients with acute coronary syndromes or those receiving endovascular prostheses. However, its efficacy has been challenged in the recent past by studies suggesting variable individual responsiveness and by new, more potent competitors, such as prasugrel and ticagrelor. But what is the actual body of evidence in support of clopidogrel? Is there any dark side of the moon? What is the role of prasugrel, which has already been approved in Europe and in the United States? And what will be the future role of ticagrelor, when approved for routine clinical practice? We hereby concisely summarize the scope of this clinical choice, providing arguments in favor and against each of the three antiplatelet agents: clopidogrel, prasugrel, and ticagrelor.

关 键 词：ACUTE CORONARY SYNDROME CLOPIDOGREL PRASUGREL Ticagrelor 

分 类 号：R541.4[医药卫生—心血管疾病]